Advances in the discovery of heterocyclic-based drugs against Alzheimer’s disease

Simple item page
dc.contributor.advisorSánchez Montero, José
dc.contributor.authorSánchez Cebrián, Juan Domingo
dc.contributor.authorAlcántara León, Andrés Rafael
dc.contributor.authorGonzález Matilla, Juan Francisco
dc.contributor.authorSánchez Montero, José
dc.date.accessioned2024-01-11T11:23:20Z
dc.date.available2024-01-11T11:23:20Z
dc.date.issued2023-11-01
dc.descriptionEste artículo fue solicitado por encargo al autor sin costes adicionales basado en la experiencia del autor sobre el tema.
dc.description.abstractIntroduction Alzheimer’s disease is a multifactorial neurodegenerative disorder characterized by beta-amyloid accumulation and tau protein hyperphosphorylation. The disease involves interconnected mechanisms, which can be clustered into two target-packs based on the affected proteins. Pack-1 focuses on beta-amyloid accumulation, oxidative stress, and metal homeostasis dysfunction, and Pack-2 involves tau protein, calcium homeostasis, and neuroinflammation. Against this background heterocyclic system, there is a powerful source of pharmacophores to develop effective small drugs to treat multifactorial diseases like Alzheimer’s. Areas covered This review highlights the most promising heterocyclic systems as potential hit candidates with multi-target capacity for the development of new drugs targeting Alzheimer’s disease. The selection of these heterocyclic systems was based on two crucial factors: their synthetic versatility and their well-documented biological properties of therapeutic potential in neurodegenerative diseases. Expert opinion The synthesis of small drugs against Alzheimer’s disease requires a multifactorial approach that targets the key pathological proteins. In this context, the utilization of heterocyclic systems, with well-established synthetic processes and facile functionalization, becomes a crucial element in the design phases. Furthermore, the selection of hit heterocyclic should be guided by a full understanding of their biological activities. Thus, the identification of promising heterocyclic scaffolds with known biological effects increases the potential to develop effective molecules against Alzheimer’s disease.
dc.description.departmentDepto. de Química en Ciencias Farmacéuticas
dc.description.facultyFac. de Farmacia
dc.description.refereedTRUE
dc.description.statuspub
dc.identifier.citationSánchez, Juan D, Alcántara, Andrés R, González, Juan F, Sánchez-Montero, José María.Advances in the discovery of heterocyclic-based drugs against Alzheimer’s disease, Expert Opinion on Drug Discovery, Noviembre 2023 18:12, 1413-28, DOI: 10.1080/17460441.2023.2264766
dc.identifier.doi10.1080/17460441.2023.2264766
dc.identifier.essn1746-045X
dc.identifier.issn1746-0441
dc.identifier.officialurlhttps://www.tandfonline.com/doi/abs/10.1080/17460441.2023.2264766
dc.identifier.urihttps://hdl.handle.net/20.500.14352/92498
dc.issue.number12
dc.journal.titleExpert Opinion on Drug Discovery
dc.language.isoeng
dc.page.final1428
dc.page.initial1413
dc.page.total16
dc.publisherTaylor and Francis
dc.rights.accessRightsrestricted access
dc.subject.cdu6
dc.subject.cdu616.894-053.9
dc.subject.keywordAlzheimer’s disease
dc.subject.keywordbenzopyrane scaffold
dc.subject.keywordbenzothiazole
dc.subject.keywordheterocyclic building blocks
dc.subject.keywordmulti-target direct ligand
dc.subject.keywordpyridine scaffold
dc.subject.keywordsmall drug
dc.subject.ucmCiencias Biomédicas
dc.subject.ucmCiencias
dc.subject.unesco24 Ciencias de la Vida
dc.subject.unesco23 Química
dc.titleAdvances in the discovery of heterocyclic-based drugs against Alzheimer’s disease
dc.typejournal article
dc.type.hasVersionVoR
dc.volume.number18
dspace.entity.typePublication
relation.isAdvisorOfPublicationace9b864-c472-4f38-86ba-9a09f24dadb9
relation.isAdvisorOfPublication.latestForDiscoveryace9b864-c472-4f38-86ba-9a09f24dadb9
relation.isAuthorOfPublication2fac9923-9d2b-459a-b51e-28736c9abe0b
relation.isAuthorOfPublicationc0d1193e-3161-4c69-af69-830b32f61932
relation.isAuthorOfPublicatione321e67a-fc49-4215-8fa2-538c7924cb7c
relation.isAuthorOfPublicationace9b864-c472-4f38-86ba-9a09f24dadb9
relation.isAuthorOfPublication.latestForDiscovery2fac9923-9d2b-459a-b51e-28736c9abe0b
Download
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
EXpero_opinion_oc_2023.pdf
Size:
3.53 MB
Format:
Adobe Portable Document Format
Download
Collections
Artículos